nicotine has been researched along with glucagon-like peptide 1 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Egecioglu, E; Engel, JA; Jerlhag, E | 1 |
| Cameron, M; Chen, Z; Duncan, A; Fowler, CD; Hayes, MR; Ishikawa, M; Kamenecka, TM; Kenny, PJ; Lee, BR; Liu, XA; Lu, Q; Pletcher, M; Tuesta, LM | 1 |
| Cruz, B; Espinoza, EJ; Flores, RJ; Nazarian, A; O'Dell, LE; Serafine, KM; Spencer, CT; Uribe, KP | 1 |
| Burkard, T; Christ-Crain, M; Coynel, D; Erlanger, TE; Hemkens, LG; Jeanloz, N; Lengsfeld, S; Meienberg, A; Speich, B; Vogt, DR; Winzeler, B; Zanchi, D | 1 |
| Clemmensen, C; Dmytriyeva, O; Ejdrup, AL; Falk, S; Gether, U; Hecksher-Sørensen, J; Jørgensen, SH; Kohlmeier, KA; Krauth, N; Ludwig, MQ; Lundø, K; Nielsen, DAG; Pers, TH; Petersen, J; Romero-Leguizamón, CR; Roostalu, U; Skovbjerg, G; Svendsen, C | 1 |
1 trial(s) available for nicotine and glucagon-like peptide 1
| Article | Year |
|---|---|
Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study.
Topics: Double-Blind Method; Glucagon-Like Peptide 1; Humans; Nicotine; Randomized Controlled Trials as Topic; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline; Weight Gain | 2023 |
4 other study(ies) available for nicotine and glucagon-like peptide 1
| Article | Year |
|---|---|
The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.
Topics: Animals; Conditioning, Psychological; Dopamine; Eating; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Incretins; Limbic System; Male; Mice; Motor Activity; Nicotine; Nucleus Accumbens; Peptides; Receptors, Glucagon; Reward; Tobacco Use Disorder; Venoms | 2013 |
GLP-1 acts on habenular avoidance circuits to control nicotine intake.
Topics: Animals; Avoidance Learning; Exenatide; Female; Gene Knockdown Techniques; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Habenula; Interpeduncular Nucleus; Male; Mice; Mice, Knockout; Neural Pathways; Nicotine; Peptides; Rats; Reward; Self Stimulation; Sitagliptin Phosphate; Solitary Nucleus; Venoms | 2017 |
Insulin modulates the strong reinforcing effects of nicotine and changes in insulin biomarkers in a rodent model of diabetes.
Topics: Animals; Behavior, Animal; Biomarkers; Body Weight; Diabetes Mellitus, Experimental; Drinking Behavior; Feeding Behavior; Glucagon-Like Peptide 1; Insulin; Insulin Receptor Substrate Proteins; Islet Amyloid Polypeptide; Leptin; Male; Nicotine; Nicotinic Agonists; Nucleus Accumbens; Rats; Rats, Wistar; Receptor, IGF Type 1; Reinforcement, Psychology; Self Administration; Ventral Tegmental Area; Water | 2019 |
GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity.
Topics: Animals; Dopamine; Glucagon-Like Peptide 1; Liraglutide; Mice; Nicotine; Obesity | 2023 |